^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Angiogenesis inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
Published date:
08/26/2022
Excerpt:
Patients with EGFR L858R mutation treated with anti-angiogenic therapy in their course of treatment had a significantly prolonged OS compared to those who had never received an anti-angiogenic agent.
DOI:
https://doi.org/10.1038/s41598-022-18889-z
